Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-16
2007-01-16
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S237200, C514S254010, C514S326000, C514S422000, C544S141000, C544S372000, C546S208000, C548S518000, C548S953000
Reexamination Certificate
active
10923619
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
REFERENCES:
patent: 6706712 (2004-03-01), Cherney
patent: 2003/0060459 (2003-03-01), Carter et al.
patent: 2003/0171218 (2003-09-01), Bojack et al.
patent: 2003/0216434 (2003-11-01), Cherney
patent: 2004/0006062 (2004-01-01), Smallheer et al.
patent: 2004/0186143 (2004-09-01), Carter et al.
patent: 2004/0235835 (2004-11-01), Carter
patent: 2004/0235836 (2004-11-01), Cherney
patent: 550924 (1993-07-01), None
patent: 63083082 (1988-04-01), None
patent: WO 97/05111 (1997-02-01), None
patent: WO 97/43257 (1997-11-01), None
patent: WO 98/01426 (1998-01-01), None
patent: WO 99/00362 (1999-01-01), None
patent: WO 99/07678 (1999-02-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 9937304 (1999-07-01), None
patent: WO 99/38844 (1999-08-01), None
patent: WO 99/40914 (1999-08-01), None
patent: WO 01/10799 (2001-02-01), None
patent: WO 01/17992 (2001-03-01), None
patent: WO 02/04416 (2002-01-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/078679 (2002-10-01), None
patent: WO 02/102372 (2002-12-01), None
patent: WO 03/005824 (2003-01-01), None
patent: WO 2004/022536 (2004-03-01), None
patent: WO 2004/071460 (2004-08-01), None
patent: WO 2004/098516 (2004-11-01), None
U.S. Appl. No. 10/922,406, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/922,726, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/923,538, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/776,828, filed Feb. 11, 2004, Cherney et al.
Trivedi et al., “Chapter 17, Chemokines: Targets for Novel Therapeutics”, Annual Reports in Medicinal Chemistry, vol. 35, pp. 191-200, 2000.
Evans et al., “Synthesis and Dopamine Receptor Modulating Activity of Novel Peptidomimetics of L-Prolyl-L-leucyl-glycinamide Featuring α,α-Disubstituted Amino Acids”, J. Med. Chem., vol. 42, pp. 1441-1447, 1999.
Costain et al., “Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats”, Peptides, vol. 20, pp. 761-767, 1999.
Batt Douglas G.
Carter Percy H.
Cherney Robert J.
Duncia John V.
Gardner Daniel S.
Bristol--Myers Squibb Company
Kosack Joseph R.
Saeed Kamal A.
VanAtten Mary K.
LandOfFree
Cyclic derivatives as modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic derivatives as modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic derivatives as modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810381